Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Estee Lauder Companies Inc (EL) vs HCA Health Inc (HCA) Price & Performance

Estee Lauder Companies IncTrade
HCA Health IncTrade

Price performance (Past 24H)

Key statistics

Estee Lauder Companies Inc vs HCA Health Inc — how do they compare? Estee Lauder Companies Inc trades at $97.58 (market cap $34.17B), while HCA Health Inc trades at $448.9 (market cap $96.35B). The key difference: HCA Health Inc is far larger — about 2.8× Estee Lauder Companies Inc's market cap, and Estee Lauder Companies Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and HCA Health Inc for 76 Days on average.

ELHCA
Market Cap
$34.17B$96.35B
Volume
3,921,4971,079,453
Sector
Consumer StaplesHealth
52-Week High
$119.61$545.13
52-Week Low
$67.23$361.32
Typical Hold Time
122 Days76 Days
Enterprise Value
$39.92B$146.88B
Dividend Yield
1.48%0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Estee Lauder Companies Inc

Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows improving earnings momentum with three consecutive quarterly beats, though 2025 results showed a net loss of $1.13B on $14.33B revenue. Analyst consensus is mixed with 48% buy ratings and a $103 price target, while recent news highlights AI partnerships and leadership changes driving strategic repositioning.

The stock presents a turnaround opportunity with strong brand positioning and digital initiatives, but faces execution risks from recent profitability challenges and high debt levels. Near-term catalysts include Q3 earnings and continued margin recovery, though competitive pressures and macroeconomic sensitivity remain headwinds for the luxury beauty sector.

HCA Health Inc

HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.

The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EL
0% Buy100% Sell
Avg holding period · 122 Days
HCA
100% Buy0% Sell
Avg holding period · 76 Days

Top news

Latest headlines on both assets

About Estee Lauder Companies Inc

Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

Read more on EL →

About HCA Health Inc

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.

Read more on HCA →